Introduction
============

HIF-1 is a transcription factor that acts as a master regulator of O~2~ homeostasis ([@B68]). It modulates the expression of an array of genes (Figure [1](#F1){ref-type="fig"}), and many of them are involved in the cellular adaptation to hypoxia ([@B70]). Vascular endothelial growth factor (VEGF), Erythropoietin (EPO), glucose transporter 1 (GLUT1), heme oxygenase 1 (HO-1), and endothelial nitric oxide (eNOS) synthase are some of the genes that are directly involved in HIF-1 mediated cellular response to hypoxia ([@B66]). As HIF-1 stabilization is an endogenous cellular mechanism to reduce hypoxia-induced injury, it is hypothesized that pre and post-hypoxic stabilization of HIF-1 by external means can enhance protection ([@B72]). Among these foreign interventions, the small molecule-based HIF-1 stabilization is widely studied and has shown promising results ([@B74]). Most of the small-molecules used for this purpose either mimic or compete with the co-factors or co-substrates of HIF-1 degradation pathway. The small molecules that are used to stabilize HIF-1α are widely known as hypoxia-mimetic agents. Some of the familiar hypoxia-mimetic agents are desferrioxamine (DFO) and cobalt chloride (CoCl~2~) ([@B86]). Apart from these small molecules, there are newly found mRNAs and other compounds which stabilize HIF-1α. In this review, we discuss the small chemical molecules and other biological compounds that have conferred protection against ischemic stroke injury *via* HIF-1 pathway stabilization.

![Network showing HIF-1 connected to its target genes (adapted from: <http://www.grnpedia.org/trrust/>). Colors inside the shape represent the type of interaction.](fcell-06-00175-g001){#F1}

HIF Structure and Pathway
=========================

Hypoxia-inducible factor belongs to the PAS family (PER-ARNT-SIM), and functionally active HIF consists of two basic helix-loop-helix (bHLH) protein subunits, alpha and beta/ARNT (aryl hydrocarbon receptor nuclear translocator). Apart from bHLH, N-terminal half of HIFs composed of Per-ARNT-Sim (PAS) homology domains. The bHLH and PAS regions are involved in the heterodimerization and DNA binding, respectively. The terminal-transactivation domains (TADs) are present in the C-terminal region of HIF, and they control the transcriptional activity of the protein (Figure [2](#F2){ref-type="fig"}) ([@B7]).

![Domain structure of human HIF subunits and isoforms.](fcell-06-00175-g002){#F2}

The alpha subunit of HIF has three isoforms, HIF-1α, HIF-2α, and HIF-3α. Likewise, the beta subunit has three isoforms, ARNT, ARNT2, and ARNT3 ([@B69]). The HIF-1α/β dimer controls the transcription of genes by binding to a core DNA motif (G/ACGTG) in hypoxia-response elements (HREs). The HIF-1β subunit is constitutively produced in the nucleus whereas the stability of HIF-1α depends on the availability of oxygen ([@B78]). Under hypoxic condition, HIF-1α is stable and transported to the nucleus. However, under the normoxic condition, HIF mediated transcription is inhibited by the HIF prolyl hydroxylases (PHDs) and asparaginyl hydroxylase (FIH). PHD2 hydroxylates the two proline residues (402 and 564) on the oxygen-dependent degradation domain (ODDD) of HIF-1α and makes it susceptible to ubiquitin-mediated proteolysis *via* von Hippel--Lindau tumour suppressor (pVHL) binding. On the contrary, FIH hydroxylases asparagine residue (803) of HIF-1α and prevents binding of the transcriptional co-activators (p300/CBP) to HIF-1α (Figure [3](#F3){ref-type="fig"}) ([@B77]). Hydroxylation of HIF α subunit by PHDs is an evolutionarily conserved mechanism of sensing the oxygen concentration inside the cell. Thus, stabilization of HIF-1α by an exogenous technique may activate transcriptional and posttranscriptional responses that will help the cell to overcome hypoxic damage ([@B51]).

![Regulation of HIF-1 during hypoxia and normoxia.](fcell-06-00175-g003){#F3}

HIF-1α degradation can be restrained by inhibiting the activity of PHDs and FIH. PHDs and FIH belong to a class of enzymes known as 2-oxoglutarate dependent dioxygenases and are the most prominent known family of non-heme oxidizing enzymes ([@B67]). There are three PHD isoforms, PHD1, PHD2 and PHD3. Even though these isoforms have a similar C-terminal catalytic domain, N-terminal sequences differ significantly ([@B73]). mRNA expression analysis revealed that the expression patterns of PHD isoforms are tissue-specific and all the isoforms play a unique role in the regulation of HIF-1α and HIF-2α ([@B3]). Both PHDs and FIH require oxygen, iron (Fe^2+^) and 2OG for the hydroxylation reaction ([@B76]).

Hypoxic microenvironments are important in the developing embryo, and they control cellular differentiation. These hypoxic microenvironments prompt the cells to activate HIFs which in turn regulate the development of the blood, vasculature, placenta, nervous system, and other organs ([@B75]). Thus, HIFs have a crucial role in embryonic development and survival. Validating the role of HIF during embryonic development, studies using HIF-1α deficient mouse embryos stopped developing by day 9 and died by day 10.5 due to extensive cell death and other abnormalities ([@B71]).

The Relevance of the HIF-1 Pathway in Ischemic Stroke
=====================================================

Cerebral stroke is a significant cause of morbidity and mortality worldwide ([@B41]). More than 80% of strokes are ischemic while the remaining is hemorrhagic. Ischemic stroke occurs when a vessel supplying blood to the brain is obstructed due to a thrombus, embolus, or other blockage ([@B32]). Prevention of neuronal death and improving the recovery following ischemic injury are the central focuses of developing stroke therapeutics. Apart from tissue plasminogen activator (tPA), no drugs are able to confer neuroprotection following ischemic stroke in clinical studies ([@B72]).

A large number of preclinical studies that used PHD inhibitors were able to show that the activation of HIF-1 can be a potentially attractive way to achieve significant neuroprotection following ischemic injury ([@B40]). Apart from stroke, PHD inhibition persistently extended neuroprotection in diverse neurological disease models ([@B77]). At the same time, a few studies observed adverse effects on brain cells upon treatment with PHD inhibitors mostly because of the activation of pro-death proteins like BNIP3 and NIX ([@B17]). As hypoxia induces HIF-1α expression, most hypoxia-mimetic agents up-regulate HIF-1α and orchestrate its downstream gene expression ([@B40]). Neuroprotection *via* HIF-1α stabilization following ischemic stroke is still a controversial topic due to its link to a vast variety of genes that mediate both adaptive and pathological processes ([@B80]). Unlike PHD inhibitors, not many FIH inhibitors are discovered, and the possibility of attaining neuroprotection *via* FIH inhibition has yet to be fully explored.

The altered expression of HIF-1 and its downstream genes during hypoxia have been very well studied in both *in vitro* and *in vivo* models ([@B70]). Several processes like angiogenesis and erythropoiesis are connected to HIF-1 stabilization. Apart from this, recent studies were able to deduce more novel phenomena and genes linked to the HIF-1 pathway ([@B79]; [@B49]). In a transient global ischemia model, HIF-1 expression was enhanced as early as 1 h in the recovery phase, and this enhanced expression lasted for 7 days ([@B11]). Besides, expression of HIF-1 regulated genes, EPO and GLUT1 were elevated during the reperfusion period. The above study also found that insulin-like growth factor-1 (IGF-1) was able to induce HIF-1 expression *in vitro* and *in vivo*.

HIF-2α has 48% structural similarity with HIF-1α, and it also activates HRE-dependent gene transcription ([@B37]). However, HIF-1α and HIF-2α have discrete transcriptional targets and perform non-redundant roles. Their expression patterns are tissue specific and the part played by these isoforms in tumor progression is contrasting ([@B64]). A study observed that HIF-1 mediated genes conferred brain hypoxia-induced tolerance rather than HIF-2 regulated genes ([@B9]). They came to this conclusion as because HIF-2α levels did not increase significantly in neuronal cells following hypoxia. Further, this study showed that adrenomedullin, propyl 4-hydroxylase α, metallothionein 1 (MT-1), mitogen-activated protein kinase phosphatase 1(MKP-1), CUGBP Elav-Like Family Member (CELF), 12-lipoxygenase and carbonic anhydrase 1 (CAR-1) are regulated by hypoxia. HIF-1α was also found to bind to the caspase-3 gene promoter region specifically. Moreover, HIF-1α and procaspase-3 showed similar expression pattern following photothrombotic cerebral ischemia ([@B36]).

Hypoxia-inducible factor responsive genes perform a significant role in the ischemic preconditioning (IPC) induced neuroprotection ([@B39]; [@B79]). Up-regulation of cytochrome P450 2C11 by HIF-1α has a role in the tolerance induced by hypoxic preconditioning (HPC) in astrocytes ([@B48]). 2-methoxyestradiol (2ME2) is a metabolite of estrogen and an inhibitor of HIF-1α ([@B90]). A study by Zhou and co-workers showed that 2ME2 aggravated the CA1 hippocampal cell death after global ischemia in rats ([@B90]). Glucose at a concentration of 25 mM up-regulated the expression of HIF-1α in rat primary cortical neurons exposed to hypoxia. Surprisingly, the study showed that along with hypoxia, a reducing environment is required for the stabilization of HIF-1α in neuronal cells ([@B27]). The above lab also found out that BCL2 interacting protein 3 (BNIP3) and BCL2 interacting protein 3 like (NIX/BNIP3L) play a role in the HIF-1α mediated neuroprotection during ischemia-reperfusion ([@B28]).

Sodium-calcium exchanger-1 (NCX1) helps in the maintenance of Na^+^ and Ca^2+^ homeostasis ([@B53]). In a recent study, it was demonstrated that NCX1 gene is controlled by HIF-1 and contributes to the HIF-1 mediated neuroprotection during brain preconditioning ([@B79]). The mammalian target of rapamycin (mTOR) belongs to a lipid kinases family, and it is involved in cell growth, survival, and proliferation ([@B84]). mTOR facilitated neuroprotection under ischemic conditions through the activation of HIF-1α, and by the regulation of VEGF expression and neuronal apoptosis in developing rat brain ([@B14]).

A few studies showed that deletion of PHD2 in neuronal cells has beneficial effects like improvement in histological and functional outcomes and neovascularisation through the promotion of HIF-VEGF axis ([@B44]). Supporting this observation, knockdown of HIF-1α before oxidative stress aggravated the impairment of learning and memory in rat model ([@B82]).

The effect of HIF-1α stabilization is not much studied in glial cells as in neurons. In a study by [@B80] explored the impact of knocking down HIF-1α specifically in astrocytes in neuron/astrocyte co-cultures exposed to hypoxia. Selective deletion of HIF-1α in astrocytes significantly protected neurons from hypoxia-induced neuronal death in co-cultures. Myeloid-specific knockout (KO) of HIF-1α resulted in faster behavioral recovery of mice subjected to MCAO ([@B10]). The HIF-1α KO mice had fewer infiltrating microglia and apoptotic neurons in the hippocampus following MCAO compared to its wild-type counterpart. The above group also observed that HIF-1α governs microglial phagocytosis and production of ROS and TNF-α under ischemic conditions. Sirtuin 1 (Sirt 1) has many vital roles in response to metabolic stress, especially cerebral ischemia ([@B43]). A study by [@B38] observed that the presence of HIF-1α plays an essential role in hypoxia-induced Sirt1 expression in oligodendrocyte progenitor cell (OPC).

The Pro and Anti-apoptotic Face of HIF-1α Stabilization in Ischemic Stroke
--------------------------------------------------------------------------

HIF-1 has both pro and anti-apoptotic features. It improved the expression of genes like EPO and VEGF that are linked to several pathways related to neuroprotection. However, it also participates in the pro-apoptotic process by stabilizing the tumor suppressor protein p53 during severe hypoxia ([@B23]). Further, it promoted cell necrosis in collaboration with calcium and calpain. It was found to increase blood-brain barrier (BBB) permeability and thus heighten brain oedema.

In agreement with the pro-apoptotic role of HIF-1, a few studies found that HIF-1deficiency can confer neuroprotection against acute hypoxia-induced cell death in mice ([@B34]). A similar trend was observed in a study by [@B13] that used HIF-1α siRNA. The authors showed that HIF-1α siRNA treatment protected neurons from ischemic injury *in vivo* through the inhibition of VEGF and apoptosis-related proteins like p53 and Caspase-3 along with HIF-1α. The *c*-glycosylated flavone, vitexin (5, 7, 4-trihydroxyflavone-8-glucoside) is a HIF-1α inhibitor ([@B54]). Inhibition of HIF-1α in the early stages of neonatal cerebral ischemia with vitexin conferred neuroprotection *in vivo*.

Further, [@B16] observed that inhibition of HIF-1α by 2ME2 5min after the hypoxia-ischemia protected the neuronal cells in the neonatal rat. There was no significant reduction in infarct volume when the treatment with the 2ME2 was delayed for 3hrs. HIF-1 inhibition also protected BBB and reduced brain oedema. While, the treatment with HIF-1α stabilizer DMOG, increased BBB permeability and brain oedema. Additionally, [@B6] showed that HIF-1 and HIF-2 are not needed for cell survival under hypoxic conditions. This study also showed that HIF-1/2 deficiency might protect neurons from early neuronal cell death and neurological impairment caused by ischemic stroke.

Additionally, [@B2] showed that the pro-death or anti-death role of HIF-1α in a cell depends on the type of death stimulus. HIF-1α overexpressing HT22 cells showed increased sensitivity to glutamate toxicity, but they were more resistant to cell death induced by camptothecin or tunicamycin or thapsigargin. When the level of p53 is low, hypoxia-induced HIF-1α triggers the transcriptional activation of adaptive genes. However, during severe and sustained hypoxia, p53 levels increase along with HIF-1α stabilization and these proteins together activate pathological genes such as BAX ([@B29]).

Tricyclodecan-9-ylxanthogenate (D609) down-regulates HIF-1α similar to 2ME2. Treatment with D609 or 2ME2 reduced infarct volume and improved neuroscore in rats following MCAO ([@B12]). These HIF-1α inhibitors decreased the expression of VEGF, BNIP3 and cleaved caspase 3. According to a study carried out by [@B52], VEGF promoted the BBB permeability *via* a nitric oxide synthase/cGMP-dependent pathway. Since VEGF is directly controlled by HIF-1, the negative effect of HIF-1α in ischemic stroke may be linked to VEGF. Information from the above studies suggests that the positive or negative effects of HIF-1 depend on cell type and the severity of hypoxia. The nature of ischemic insult also plays a role in determining whether HIF-1α will advocate pro-death or pro-survival pathways ([@B72]).

Biphasic Expression Pattern of HIF-1α Following Ischemic Injury
---------------------------------------------------------------

Biphasic expression pattern of HIF-1α was observed in some of the studies following *in vitro* and *in vivo* models of cerebral ischemia. A study by [@B47] monitored the changes in the HIF-1α gene and protein expression at different time points in a middle cerebral artery occlusion (MCAO) model using an embolus (eMCAO). HIF-1α mRNA level gradually increased following ischemia and peaked at 6 h. After that, it slowly decreased and came to a low level at 24 h. A similar pattern of expression was observed from 24 to 168 h reaching the peak at 72 h. An exactly same trend was seen in the case of HIF-1α protein expression.

According to a study by [@B83], inhibition of HIF-1α in the early time point (0.5 h after ischemic stress) abated brain injury and oedema. While inhibiting HIF-1α at a later stage (8 h after ischemic injury) increased brain damage and decreased VEGF expression. Theoretically, HIF-1α induction at the early time points of ischemia activates apoptotic pathways, and at late time points, it promotes cell survival pathways. Comparable expression pattern of HIF-1α was observed in other study carried out by [@B5] in the MCAO model.

In neonatal rat brain, upon MCAO, HIF-1α protein expression was elevated immediately (0 h, without reperfusion) and peaked at 8 h, and then deteriorated at 24 h after reperfusion ([@B55]). VEGF protein expression was also similar to that of HIF-1α. This variation shows the biphasic nature of HIF-1 expression following cerebral ischemia in neonatal brain. When compared to the expression pattern in neuronal cells, similar alterations in expression of HIF-1α mRNA and protein were observed in microglia cells following exposure to hypoxic conditions ([@B81]). These studies have enhanced our understanding of the dual and contrasting roles of HIF-1α expression in neurons following ischemic stroke. To a certain extent, this biphasic expression pattern of HIF-1α will decide the time window of administration of drugs that act *via* HIF-1α stabilization for maximum protection.

Hypoxia Mimetic Agents in Ischemic Stroke
=========================================

The term "hypoxia mimetic agent" has been widely used to indicate biological or chemical molecules which are used to up-regulate HIF-1α expression. They do it either *via* PHDs inhibition or some other mechanisms. Here, in this review, HIF-1α stabilizers are broadly classified according to the involvement of PHDs in the stabilization process.

HIF-1α Up-Regulation *via* Inhibition of PHD Pathway
----------------------------------------------------

Most of the HIF-1α up-regulators act *via* PHD inhibition. Currently, the following interventions are used stabilize HIF-1α and mimic hypoxic conditions *via* PHD inhibition: (a) reduce Fe^2+^ availability using iron chelators; (b) introduce metal ions that will compete with Fe^2+^; (c) use 2OG analogs. HIF-1α stabilizers that do not come under any of the above categories are discussed under a separate subheading.

### Iron Chelators and Competitors

Iron chelators are small molecules that bind very tightly to iron and reduce the amount of free divalent iron available for PHD mediated HIF hydroxylation reaction ([@B61]). Deferoxamine mesylate (DFO) is a widely used iron chelator that removes excess iron from the body ([@B25]). Previously, it was thought that iron chelators prevent oxidative injury by obstructing hydroxyl radical formation but later studies revealed that iron chelators inhibit the action of PHDs and upregulate HIF-1 expression ([@B74]). Alternatively, iron competitors (mostly divalent metal ions) that compete with Fe^2+^ in the PHD mediated HIF-1 hydroxylation process can be used. Although there are several iron competitors like Ni^2+^ and Mn2^+^, Co^2+^ in the form of cobalt chloride (CoCl~2~) is the most widely used iron competitor for PHD inhibition ([@B24]). A recent study by [@B57] reported that Zn^2+^ could selectively inhibit PHD3 over PHD2.

A study by [@B85] was one of the first studies to explore HIF-1 mediated neuroprotection by iron chelators following hypoxic stress. In this study, iron chelators, DFO and mimosine (MIM) protected embryonic cortical neurons from glutathione depletion and oxidative stress-induced cell death at a concentration of 100 μM. Neuroprotective capabilities of these agents were also comparable to their ability to augment DNA binding of HIF-1. These compounds also up-regulated mRNA and protein expression of HIF-1 controlled genes. Likewise, cell death induced by depletion of glutathione was decreased significantly by treatment with CoCl~2~ at a concentration \> 200 μM, a competitive inhibitor of iron. CoCl~2~ also elevated the HIF-1α protein expression.

Subsequently, several studies explored the ability of iron chelators for HIF-1 mediated neuroprotection against hypoxic injury. [@B74] investigated the mechanism by which DFO offered protection in neuronal cells. In cortical neurons, HIF-1α was stabilized upon treatment with 100 μM DFO and protected cells from oxidative glutamate toxicity. Similarly, [@B62] demonstrated the neuroprotective effect of DFO against OGD injury in purified cortical neurons. DFO at a concentration of 150 μM/L induced 47% reduction in cell death in primary cortical neurons subjected to OGD.

Compound A is a novel proprietary (Fibrogen Inc., United States) small molecule iron chelator. It stabilized HIF-1α in cortical neurons and increased the expression of HIF-1 targeted genes at a concentration of 40 μM ([@B74]). It also conferred protection against oxidative glutamate toxicity. In addition to its protective effect in *in vitro* studies, treatment with 100 mg/kg of compound A, stabilized HIF-1 in rat brain within 3h. It also reduced infarct volume by 67%, compared to control littermates. In hippocampal neurons from newborn mice, pretreatment with 10 mM/L DFO decreased OGD induced cell death by 45% compared to the control group. The protection conferred by DFO diminished upon cell's transfection with anti-HIF-1α. This finding suggests that the protection by DFO is through HIF-1α induction ([@B30]).

Prolyl hydroxylases isoforms differ in their expression patterns, tissue distribution, subcellular localization, and their ability to hydroxylate HIF-1α ([@B73]). Based on these characteristics, Siddiq and co-workers hypothesized that the neuroprotection conferred by PHD inhibitors are PHD isoform-specific and independent of HIF-1. In this regard, they investigated the role of PHD and HIF isoforms in giving neuroprotection against normoxic oxidative death by the treatment of PHD inhibitors in primary rat neurons. When compared to a previous *in vitro* study carried out by [@B85], they observed something distinctive in this study. They noted that the prevention of normoxic oxidative neuronal death by DFO is through the inhibition of PHD1 and HIF-1α doesn't have any role in this mechanism. They also noted that its HIF-2α, not HIF-1α controls the sensitivity to normoxic oxidative neuronal death.

In comparison to adult CNS, the neonatal brain is highly sensitive to the availability of essential substrates. Treatment with 60 mg/kg of CoCl~2~ and 200 mg/kg of DFO increased the level of HIF-1α protein in rat pups compared to the vehicle-injected controls ([@B8]). Compared with that in vehicle-injected controls, preconditioning with DFO and CoCl~2~ 24h before hypoxia-ischemia gave 56 and 75% protection, respectively.

Desferrioxamine promoted the binding of HIF-1 to DNA and transcription of EPO *in vivo*. There was a 20-fold increase in DNA binding of HIF-1 upon DFO application. The tolerance induced by DFO was time and dosage-dependent ([@B62]). Expression of GLUT1 protein was elevated in rat brain by the treatment of 300 mg/kg of DFO. Brain lesion area and whole brain cell loss reduced upon treatment with DFO. Notably, DFO treatment didn't affect striatal lesion but provided a 20% reduction in cortical injury compared with the vehicle group. Likewise, there was a 62% decrease in thalamic shrinkage by the treatment of DFO in comparison with vehicle-treated animals. Neurological score and sensorimotor performances also improved upon treatment with DFO ([@B26]).

Deferasirox (DFR) is an orally administrated iron chelator and is in clinical use with high tolerance ([@B33]). As previously observed in the study by [@B73]; [@B89] also showed that neuroprotection conferred by DFO and DFR following MCAO does not require HIF-1α in mice. They also observed that both DFO and DFR do not induce expression of HIF-1 target genes.

2, 2′-dipyridyl (DP) is a liposoluble iron chelator, and it is used to regulate HIF-1α expression up. Experiments show that DP treatment reduced infarct volume and maximal infarct area and thus significantly decreased histological damage ([@B19]). There was a 42% reduction of infarct volume and a 25% decrease in the maximal infarct area upon treatment with DP. It protected both endothelial cells and neurons from ischemic injury. Besides, DP treatment in rats reduced ischemia-induced reactive oxygen species (ROS) production and suppressed the transformation of penumbra into infarct.

In chemical photothrombosis stroke models, DP treatment hindered the progression of infarct core and the surrounding regions ([@B35]). The density of apoptotic bodies reduced upon treatment with DP in both infarct core and surrounding pale region. Compared to the vehicle-treated animals, DP treatment decreased and limited the DNA fragmentation only to P1 region. Upon treatment with DP, there was a significant reduction in procaspase-9 cleavage in the P1 and P2 regions. Similarly, procaspase-3 cleavage was decreased in these regions. There was also a drop in cleaved caspase-3 in the entire infarct region upon treatment with DP *in vivo*.

Neuroprotection achieved by DP post-treatment was lower when compared with DP pretreatment ([@B5]). Further, the protective effect produced through the administration of DP before or after MCAO was significantly attenuated but not completely abolished in neuron-specific HIF-1α-deficient mice. This shows the involvement of an alternative mechanism in giving neuroprotection upon DP treatment. Similarly, another study ([@B39]) observed that there was no change in expression of genes modulated by HIF-1 upon preconditioning with CoCl~2~ suggesting a surrogate process may be involved in the induction of tolerance by CoCl~2~ in the brain of newborn rats.

### 2OG Analogs

Numerous hydroxybenzenes, hydroxybenzoic acids and analogous compounds have similar structural features as both 2-oxoglutarate and ascorbate. They can compete with these molecules and inhibit prolyl 4-hydroxylase enzymes ([@B50]). 10 μM dihydroxybenzoic acid (DHB) stabilized HIF-1α and increased the transcription of HIF-1 dependent genes. DHB conferred protection to cortical neurons exposed to oxidative glutamate toxicity ([@B74]).

*N*-oxalylglycine can inhibit most of the 2OG-dependent oxygenases and other enzymes ([@B1]). Dimethyloxalylglycine (DMOG) is a readily cell permeable ester of *N*-oxalylglycine. DMOG has a similar structure to 2OG. It competes with PHD co-substrate, 2OG and prevents HIF-1α degradation ([@B73]; [@B58]). Twenty four hour treatment with DMOG increased the protein expression of HIF-1α and mRNA levels of VEGF in cortical neurons growing under normoxic condition. Preconditioning with DMOG for 24 h before OGD significantly reduced OGD-induced cell death in cortical neuron cell. Similarly, post-treatment with DMOG also reduced cell death. This protection abrogated by the pretreatment of HIF-1α-shRNA showed the need of HIF-1α for achieving neuroprotection using PHD inhibitors ([@B59]).

*In vivo* stabilization of HIF-1 was observed within 6 h of administration of DHB. There was a significant reduction of infarct volume upon DHB treatment compared to control ([@B74]). Studies in mice showed that intraperitoneal injection of DMOG increased the level of HIF-1α protein up to threefold in a time-dependent manner in mouse brain cortex. It also elevated the expression of HIF-1 controlled genes that regulate erythropoietin and pyruvate dehydrogenase kinase-1. Further, post-OGD treatment with DMOG reduced the infarct volume in an animal stroke model. In addition to this, it stimulated pro-apoptotic caspase-3 protein, curtailed behavioral deficits and decreased the loss of local blood flow in the middle cerebral artery territory. These attributes nullified upon inhibition of HIF-1α by Digoxin ([@B59]).

In another study by [@B58], DMOG reduced ischemic injury and improved behavior and neuroscore after both permanent and transient MCAO in adult male Wistar rats. Regional cerebral blood flow also improved. There was also a reduction in the amount of BBB breakdown. A consistent increase in the expression of both mRNA and protein levels of VEGF and endothelial nitric oxide synthase observed after DMOG treatment. As seen in the case of DFO, a study by Siddiq and co-workers suggested that the neuroprotection exerted by DMOG and DHF does not require HIF-1α stabilization and instead inhibit the PHD1 isoform ([@B74]).

### PHD Inhibitors With an Alternative Mechanism of Action

This section also includes HIF-1α stabilizers, but their exact mechanism of PHD inhibition is not either mentioned in the source paper or different from the above classification. These molecules may act by binding directly to the active site of the PHDs without mimicking 2OG or chelating the iron atom. A study ([@B65]) focusing on reducing neuronal death following ischemic stroke *via* maintaining BBB integrity used a novel PHD inhibitor, FG-4497. HIF-1α stabilized upon treatment with FG-4497 in both primary murine astrocytes and the murine cerebrovascular endothelial cell line. FG-4497's capability to inhibit HIF-1α proteolysis was higher than DMOG. It also up-regulated the transcription of HIF-1 targeted genes VEGF and EPO. In mouse hippocampal culture, FG-4497 significantly enhanced the survival of cells following OGD.

Intraperitoneal injection of FG-4497 elevated the amount of HIF-1α in cerebral tissue and significantly reduced infarct size compared to vehicle-treated mice ([@B65]). FG-4497 pre-treatment reduces infarct volume in transient MCAO models. Post-treatment with FG-4497 also showed neuroprotection following permanent cerebral ischemia.

2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetic acid (IOX3) is a novel inhibitor of PHDs ([@B15]). It has a structure similar to FG2216, which promoted the expression of EPO *in vivo*. Administration of IOX3 24h before a MCAO improved neuroscores and reduced infarct volume in mice. It also elevated the level of HIF-1α protein and EPO expression. However, injection of IOX3 soon before the MCAO showed no significant neuroprotection. IOX3 also prevented BBB disruption when treated 24 h before MCAO.

GSK360A is an orally active PHD inhibitor that has reduced myocardial infarct size in the rat and murine heart ([@B60]). Treatment with GSK360A increased the plasma EPO and VEGF mRNA and protein levels ([@B91]). When compared to the vehicle-treated group, pretreatment with GSK360A reduced post-stroke surgery neurological deficits, cognitive dysfunction and infarct volume 4 weeks after MCAO. Another novel PHD inhibitor, TM6008 decreased cell death and up-regulated HIF-1α levels *in vitro*. It also induced the protein expression of HIF-1 downstream genes, HO-1, EPO, and glucose transporter 3 (GLUT3) ([@B42]).

Lately, molecular docking and simulation studies carried out in our lab found folic acid (FA) to be an ideal compound that binds to PHD2, FIH and pVHL alike at their HIF-1α binding region ([@B18]). *In vitro* experiments showed that post-ischemic treatment with FA up-regulated HIF-1 expression and its downstream genes. Further, FA conferred neuroprotection following OGD and promoted angiogenesis.

HIF-1α Up-Regulation Without the Inhibition of PHDs
---------------------------------------------------

Non-PHD HIF-1α stabilizers relay on a mechanism other than the classical PHD-HIF pathway to up-regulates HIF-1α. Compared to the conventional PHD inhibitors, these molecules are newly discovered. HIF-1α stabilization through IPC is not discussed in this review as it is out of the scope of the title theme.

A study by [@B47] showed that miR-335 is a direct regulator of HIF-1α, and has shown an inverse expression profile both *in vivo* and *in vitro* ischemic models. Treatment with miR-335 decreased infarct volume immediately after MCAO, and miR-335 inhibitor was found to be beneficial at 24 h after MCAO in a rat model. Thus, regulation of HIF-1α expression by miR-335 at various time points manipulated the genes required for adaption to hypoxia and ultimately resulted in the reduction of infarct volume.

Preconditioning with 1.5% isoflurane protected neurons from oxygen-glucose deprivation (OGD) injury by the induction of HIF-1α protein, and this activation is linked to the Erk1/2 pathway ([@B46]). Further, a recent study by the above group showed the neuroprotection provided by isoflurane post-conditioning *via* HIF-1α stabilization ([@B45]). Post-ischemic treatment with isoflurane reduced the infarct volume and improved neurological scores. Both post and pre-ischemic treatment with isoflurane treatment up-regulated iNOS mRNA level.

*N*-acetylcysteine (NAC) has various therapeutic properties, and it is an antioxidant ([@B20]). It is also protected the brain from ischemic injury in preclinical studies ([@B88]). A study by Zhang and colleagues observed that pretreatment with 150 mg/kg of NAC increased the protein levels of HIF-1α, EPO and GLUT3 in the ipsilateral hemispheres of rodents. The group also found out that HIF-1 is responsible for NAC mediated neuroprotection following MCAO. NAC treatment up-regulated heat shock protein 90 (Hsp90) expression and in turn interaction of Hsp90 to HIF-1.

A study by [@B4] reported that 20S and 26S proteasomal pathways were involved in HIF-1α degradation in ischemic neurons. For the *in vitro* studies, MG-132, a proteasome inhibitor was used and it stabilized HIF-1α protein better than DMOG. A combination of MG-132 and DMOG had a better effect on HIF-1α stabilization than them individually. Further, they observed that treatment with epoxomicin, another proteasome inhibitor reduced infarct size and brain oedema following oxidative stress *in vivo* by the stabilization of HIF-1α. *In vivo* also a combination of epoxomicin and DMOG yielded better protection. The study also showed that proteasome inhibitors are more effective than PHD inhibitors in providing HIF-1α stabilization and neuroprotection.

[@B21] tested a novel proteasome inhibitor BSc2118 for its neuroprotective activity following ischemic stroke. 12h pre-ischemic injection of BSc2118 conferred significant reduction of infarct volumes on day four. BSc2118 yielded long-term neuroprotection for as long as 3 months with the post-stroke treatment. Apart from reducing the infarct volume, BSc2118 was able to decrease brain oedema, and BBB break down. Further, it promoted both angiogenesis and neurogenesis. Using the knock out studies, they concluded that all these positive effects of BSc2118 were mediated by HIF-1α.

Tilorone is a low molecular weight antiviral agent ([@B22]). In a study by [@B63] tilorone at a concentration of 100 mg/kg increased the stabilization of HIF-1α and elevated the expression of its downstream genes *in vitro*. The stabilization of HIF-1α by tilorone was independent of iron chelation and HIF-PHD inhibition *in vitro*. Tilorone also significantly reduced infarct volume *in vivo* following MCAO.

Huang-Lian-Jie-Du-Tang (HLJDT) is a traditional Chinese medicine with properties like heat-clearing and detoxification ([@B87]). In cerebral cortical neurons, pretreatment with HLJDT increased HIF-1α, EPO and VEGF levels and protected the cells against OGD. It decreased ischemia-induced apoptosis and promoted proliferation in neuronal cells. HLJDT also significantly reduced cerebral infarction; cerebral water content and improved neurological deficient score in MCAO rat models. All the hypoxia mimetic agents discussed in this review either act by inhibiting PHDs or other mechanisms and they ultimately regulate the expression of HIF-1. Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} gives a summary of the studies that used hypoxia-mimetic agents to obtain neuroprotection following ischemic injury.

###### 

Details about the studies that used non-PHD HIF-1α stabilizers as hypoxia-mimetic agents.

  Sl. No.   Study    Compound(s)          Type of compound       Time of administration           Stroke model(s)   Cell/animal type
  --------- -------- -------------------- ---------------------- -------------------------------- ----------------- -----------------------------------------------------
  1         [@B47]   miR-335              microRNA               Immediately or 24 h after MCAO   eMCAO             Male Wistar rats
  2         [@B46]   Isoflurane           Anesthetic             24 h before OGD                  OGD               Hippocampal neurons
  3         [@B45]   Isoflurane                                  Not specified (post-OGD/MCAO)    OGD/MCAO          Male Sprague--Dawley rats; Primary cortical neurons
  4         [@B88]   NAC                  Antioxidant            30 min before MCAO               MCAO              Male Sprague--Dawley rats
  5         [@B4]    MG-132; Epoxomicin   Proteasome inhibitor   24 h before MCAO                 OGD/MCAO          C57/BL/6 male mice; Primary cortical neurons
  6         [@B21]   BSc2118              Proteasome inhibitor   12 h before MCAO                 MCAO              Male C57BL/6N mice
  7         [@B63]   Tilorone             Antiviral agent        24 h before MCAO                 MCAO              Male Sprague--Dawley rats

###### 

Details about the studies that used PHD inhibitors as hypoxia-mimetic agents.

  Sl. No.   Study    Compound(s)   Type of compound   Time of administration                                                            Stroke model(s)                               Cell/animal type
  --------- -------- ------------- ------------------ --------------------------------------------------------------------------------- --------------------------------------------- -----------------------------------------------------------------------------------
  1         [@B85]   DFO           Iron chelator      Immediately or up to 10 h after HCA^∗^ treatment                                  Glutathione depletion model                   Rat primary neurons
                     Mimosine      Iron chelator                                                                                                                                      
                     CoCl~2~       Iron competitor                                                                                                                                    
  2         [@B74]   DFO                              6 h before MCAO                                                                   Glutamate-mediated excitotoxicity/MCAO        Rat primary neurons; Adult male Sprague--Dawley rats
                     DHB           2OG analog                                                                                                                                         
                     Compound A    Iron chelator                                                                                                                                      
  3         [@B8]    DFO                              24 h before ligation                                                              Unilateral carotid artery ligation            Male and female Sprague--Dawley rats
                     CoCl2                                                                                                                                                            
  4         [@B62]   DFO                              48 or 72 h before OGD/MCAO                                                        OGD/MCAO                                      Rat primary neurons; Male Wistar rats
  5         [@B26]   DFO                              Before and/or shortly after MCAO                                                  MCAO                                          Sprague--Dawley rats
  6         [@B5]    DFO                              6 h before or after MCAO                                                          MCAO                                          Transgenic C57BL6/J male mice
                     DHB                                                                                                                                                              
                     DP            Iron chelator                                                                                                                                      
  7         [@B73]   DFO                              Before or along with HCA                                                          Glutathione depletion model                   HT22 murine hippocampal cells
                     DHB                                                                                                                                                              
                     DMOG          2OG analog                                                                                                                                         
  8         [@B30]   DFO                              1 h before and during OGD                                                         OGD                                           Hippocampal cells
  9         [@B56]   DFO                              Immediately after MCAO                                                            MCAO                                          Female Sprague--Dawley rats
  10        [@B31]   DFO                              Multiple times before or after MCAO                                               MCAO                                          Male Sprague--Dawley rats
  11        [@B89]   DFO                              Every day up to 4 weeks before MCAO                                               MCAO                                          Mice
                     DFR           Iron chelator                                                                                                                                      
  12        [@B39]   CoCl~2~                          24 h before MCAO                                                                  MCAO                                          Male and female Sprague--Dawley rats
  13        [@B19]   DP            Iron chelator      15 min before and 1 h after occlusion                                             Cortical photothrombotic vascular occlusion   Adult male Wistar rats
  14        [@B35]   DP                               15 min before and 1 h after occlusion                                             Cortical photothrombotic vascular occlusion   Adult male Wistar rats
  15        [@B59]   DMOG                             24 h before OGD and 2 h after initiation of OGD; 30 or 60 min after reperfusion   OGD/MCAO                                      Primary neurons; Adult male B6129PF2/J mice
  16        [@B58]   DMOG                             Multiple times before and one time after MCAO                                     Permanent or transient MCAO                   Adult male Wistar rats
  17        [@B65]   FG-4497       Not specified      6, 24, and 48 h during OGD; 6 h before or soon after MCAO                         MCAO                                          Primary murine astrocytes and HT-22 hippocampal neuronal cells; Male C57BL/6 mice
  18        [@B15]   IOX3          Not specified      One day or immediately before MCAO                                                MCAO                                          Male C57/B6 mice
  19        [@B91]   GSK360A       Not specified      18 and 5 h before MCAO                                                            MCAO                                          Male Sprague--Dawley rats
  20        [@B42]   TM6008        Not specified      Immediately after hypoxia                                                         Anaerobic chamber                             SHSY-5Y cells
  21        [@B87]   HLJDT         Unknown            24 h before OGD or MCAO                                                           OGD; MCAO                                     Rat primary neurons; Male Sprague--Dawley rats

∗

HCA, homocysteic acid.

Conclusion
==========

Hypoxia causes the cell to accumulate HIF-1 in the nucleus and up-regulate specific HIF-1 targeted genes so that cells can overcome the adverse condition. All the hypoxia mimetic agents are designed to act in such a way to boost this endogenous mechanism. One way to do this is through the inhibition of PHDs. These PHD inhibitors come under either the iron chelator and competitive inhibitor category or the 2OG analog category. Other molecules rely on mechanisms other than PHD inhibition to stabilize HIF-1α. Apart from a few newly discovered molecules, widely used hypoxia-mimetic agents are DFO, DHB, CoCl~2~, DP, and DMOG. These agents up-regulated HIF-1α levels and regulated its downstream genes.

Further, these agents conferred significant neuroprotection both *in vitro* and *in vivo* experiments. As the progression of ischemic brain injury is multifactorial, each of the HIF-1 regulated genes influences various cellular processes of infarct advancement at different time points. In most of the cases, treatment with hypoxia-mimetic agents several hours before or after the induction of hypoxia bestowed greater protection compared to treatment with these agents soon before or after oxidative stress. The neuroprotection conferred by these agents also depends on the cell type and magnitude of the ischemic injury.

However, there are studies which did not show neuroprotection *via* HIF-1 up-regulation and even demonstrated its pro-death features. Therefore, the extent of neuroprotection provided by HIF-1 in the case of ischemic injury is still a debatable topic. Nevertheless, in light of studies discussed in this review (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}); we can conclude that HIF-1's beneficial characteristics appear to outweigh its adverse effects. Many of the harmful effects of HIF-1α can be eliminated by carefully choosing the time of administration of HIF-1α stabilizers. Type of hypoxia mimetic agent used, nature of ischemic injury and kind of cell targeted by the treatment are the other factors which affect the neuroprotection bestowed by HIF-1α stabilizers.

One drawback of using the conventional mimetic agent is that several other enzymes use Fe^2+^ and 2OG as co-factor or co-substrate. Therefore the use of iron chelators, competitive iron inhibitors and 2OG analogs can create undesired interference of different pathways. In this regard, the introductions of novel drugs that can specifically inhibit PHDs or stabilize HIF-1α through other mechanisms need more consideration. Specificity of PHD inhibitors can be achieved by the development of molecules that can bind to the active sites in PHDs. These agents could be analogous to the parts of HIF-1α that interact with PHDs. The possibility of stabilizing HIF-1α *via* FIH inhibition has not received much attention and warrants further exploration.
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